Esperion Therapeutics prices upsized IPO at $14, the midpoint of the range

By
A A A

Esperion Therapeutics, which is developing a treatment for elevated levels of low-density lipoprotein cholesterol, raised $70 million by offering 5.0 million shares at $14, within the range of $13 to $15. Esperion Therapeutics plans to list on the NASDAQ under the symbol ESPR. Esperion Therapeutics initially filed confidentially on April 12, 2013. Credit Suisse and Citi acted as joint bookrunners on the deal.



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: News Headlines , IPOs

Referenced Stocks: ESPR

Renaissance Capital

Renaissance Capital

More from Renaissance Capital:

Related Videos

Stocks

Referenced

100%

Most Active by Volume

86,692,048
  • $16.82 ▼ 1.35%
66,073,054
  • $13.30 ▼ 6.27%
54,801,491
  • $14.59 ▼ 1.35%
54,305,010
  • $76.55 ▼ 3.15%
53,982,567
  • $3.42 ▼ 2.01%
53,146,472
  • $97.21 ▼ 1.60%
50,334,521
  • $99.18 ▼ 1.56%
44,049,276
  • $25.03 ▼ 0.56%
As of 10/1/2014, 04:15 PM

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com